United Therapeutics (UTHR) Other Accumulated Expenses (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Other Accumulated Expenses data on file, last reported at $100.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 34.76% year-over-year to $100.8 million; the trailing twelve-month figure through Mar 2026 stood at $100.8 million (down 34.76% YoY), and the FY2025 full-year result was $72.6 million, down 22.44% from the prior year.
• Other Accumulated Expenses rose to $100.8 million in Q1 2026, from $72.6 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $154.5 million in Q1 2025 to a low of $32.5 million in Q4 2022.
• A 5-year average of $74.4 million and a median of $72.6 million in 2025 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses slumped 36.51% in 2023 and jumped 227.2% in 2024, its largest moves.
• Tracing UTHR's Other Accumulated Expenses over 5 years: stood at $32.5 million in 2022, then jumped by 118.46% to $71.0 million in 2023, then jumped by 31.83% to $93.6 million in 2024, then declined by 22.44% to $72.6 million in 2025, then jumped by 38.84% to $100.8 million in 2026.
• Business Quant data shows UTHR's Other Accumulated Expenses at $100.8 million in Q1 2026, $72.6 million in Q4 2025, and $78.3 million in Q3 2025.